Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety,…
I'd like to check my clonazepam dose — am I in the 1-2 mg range where benefit plateaus, and if I'm above it, is the extra dose doing anything but adding side effects?
Reasonable evidence with real limitations. how we score evidence
In 413 people with panic disorder randomized to placebo or five fixed doses of clonazepam, daily doses of 1 mg and above reduced panic attacks equally well, and 1-2 mg/day gave the best balance of benefit against side effects such as sleepiness and unsteadiness, which climbed at 3-4 mg.
Worth asking
I'd like to check my clonazepam dose — am I in the 1-2 mg range where benefit plateaus, and if I'm above it, is the extra dose doing anything but adding side effects?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Seizure disorders (Lennox-Gastaut syndrome, akinetic and myoclonic seizures; absence seizures unresponsive to succinimides)
- Panic disorder, with or without agoraphobia
Source
Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance — Rosenbaum JF, et al. (1997)
Reputable peer-reviewed journal
Read the source: https://doi.org/10.1097/00004714-199710000-00008
DOI: 10.1097/00004714-199710000-00008
How this was scored
- Study design
- Randomised controlled trial
- Funding
- Funding not disclosed
- Published in
- Reputable peer-reviewed journal
- Sample size
- 413
- Preregistered
- No
- Conflicts disclosed
- No
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "moderate evidence". Reasonable evidence with real limitations. It scores 61 out of 100 on our published rubric. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance — Rosenbaum JF, et al. (1997). Published in: Reputable peer-reviewed journal. DOI: 10.1097/00004714-199710000-00008. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Randomised controlled trial. Funding: Funding not disclosed. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is clonazepam (Klonopin, Rivotril), klonopin, rivotril FDA approved?
Yes — FDA approved for Seizure disorders (Lennox-Gastaut syndrome, akinetic and myoclonic seizures; absence seizures unresponsive to succinimides), Panic disorder, with or without agoraphobia. Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.